



ACC.15

TCT@ACC-12 | innovation in intervention

A304
JACC March 17, 2015
Volume 65, Issue 10S Arrhythmias and Clinical EP

LEFT ATRIAL APPENDAGE OCCLUSION DEVICE AND NOVEL ORAL ANTICOAGULANTS VERSUS WARFARIN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROL TRIALS

Poster Contributions

Poster Hall B1

Saturday, March 14, 2015, 10:00 a.m.-10:45 a.m.

Session Title: What's Going On in the World of Atrial Fibrillation?

Abstract Category: 4. Arrhythmias and Clinical EP: AF/SVT

Presentation Number: 1115-239

Authors: *David Felipe Briceno, Pedro Villablanca Spinetto, Nicole Cyrille, Daniele Massera, Eric Bader, Eric Manheimer, Philip Aagaard, Kevin Ferrick, Jay Gross, Soo Gyum Kim, Andrew Krumerman, Eugen Palma, Nils Guttenplan, John Fisher, Mario Garcia, Andrea Natale, Luigi Di Biase, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA, Texas Cardiac Arrhythmia Institute, Austin, TX, USA*


Background: Different strategies have been evaluated for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). We sought to evaluate the efficacy and safety of different approaches compared to standard therapy with warfarin.

Methods: We conducted electronic database searches of phase III randomized controlled trials (RCT). Efficacy outcomes were stroke or systemic embolism (SSE) and all-cause mortality. Safety outcome was major bleeding or procedure related complications. A random-effect model was used to obtain a summary effect. Odds ratios (OR) and 95% confidence intervals (CI) were computed using the Mantel-Haenszel method.


Results: Eight RCTs were included (n=80,684 patients). The comparison groups were novel oral anticoagulants (NOAC), and Watchman left atrial appendage occlusion device (Device) against warfarin. There was a significant difference favoring NOAC for SSE (OR 0.83, 95% CI 0.72-0.97; p=0.01), all-cause mortality (OR 0.88, 95% CI 0.83-0.93; p<0.001) and safety outcomes (OR 0.79, 95% CI 0.64-0.97; p=0.026) compared to Device. No evidence of significant publication bias was found.

Conclusion: NOAC is superior to warfarin and Device when compared to warfarin as standard therapy for stroke prevention in NVAF. Device is a reasonable non-inferior alternative to warfarin for stroke prevention when anticoagulation is contraindicated.

Stroke or systemic embolism



Death



Safety

